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Fig. 1ESI.  Active site of E. coli IspE from the ternary complex with CDP-ME and 
the non-hydrolysable ATP analogue 5’-adenyl-β,γ-amidotriphosphate (AppNp) (PDB 
code: 1OJ4).19  Colour code: protein skeleton: C: grey; inhibitor skeleton: C: green; 
O: red; N: blue; P: orange. The colour code is maintained throughout the ESI, if not 
otherwise stated. 
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Fig. 2ESI.  MOLOC-generated molecular model of inhibitor 22 in the active site of 
E. coli IspE (PDB code: 1OJ4).19  Colour code: S: yellow.  Distances are given in Å.  
The units for the indicated distances are maintained throughout the ESI. 
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Fig. 3ESI.  Exemplary IC50 curves for inhibition of E. coli IspE by inhibitors (±)-9 (a) 
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Fig. 4ESI.  Exemplary kinetics for the inhibition of E. coli IspE by inhibitors (±)-9 (a) 
and 22 (b).  Inhibitor concentrations were 0, 2, 4, 8, 16 and 32 μM (a) and 0, 8, 16, 31, 
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Fig. 5ESI.  MOLOC-generated molecular model of (±)-3,12 showing hydrophobic 
contacts in the small, hydrophobic pocket of E. coli IspE (PDB code: 1OJ4).19 
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Fig 6ESI.  MOLOC-generated molecular model of inhibitors featuring n-alkyl chains 
bound within the active site of E. coli IspE (PDB code: 1OJ4).19  Colour code: 
C-skeleton of (±)-212: green, C-skeleton of (±)-312: cyan, C-skeleton of (±)-412: 
magenta, C-skeleton of (±)-6: light pink. 
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Fig 7ESI.  MOLOC-generated molecular model of inhibitor (±)-16 in the active site 
of E. coli IspE (PDB code:1OJ4).19 
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Fig. 8ESI.  a) Omit difference density maps for 22 in the active site of A. aeolicus 
IspE.  The purple chicken wire represents the Fo–Fc, acalc calculation, where Fo and 
Fc are the observed and calculated structure factors, respectively and acalc the model 
phases calculated from all atomic positions except for the ligand itself; contoured at 
the 1 σ  (left ) and 2.5 σ level (right).  Colour code: protein skeleton: C: light pink; 
inhibitor skeleton: C: cyan.  b) X-ray crystal structure of A. aeolicus IspE co-
crystallised with 22 and diphosphate (PDB code: 2VF3).  Shown is active site A.  
c) Superposition of 22, as observed in active site A of A. aeolicus IspE, onto 22, as 
observed in active site B of A. aeolicus IspE (PDB code: 2VF3).  Colour code: 
C-skeleton of 22 as observed in active site A: light pink. 
a) 
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Fig. 9ESI.  Superposition of the active sites from the X-ray crystal structures of 
A. aeolicus IspE with a cytidine-based ligand and 22 (PDB codes: 2V2V and 2VF3, 
respectively).13  a) Gly-rich loop;  b) Cytidine-binding pocket.  Colour code: protein 
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Scheme 1ESI.  Synthesis of inhibitors (±)-5 – (±)-8 and (±)-11.  (i) Et3N, CH2Cl2, 
0 °C → 25 °C, 15–30 min, 30,33 35 (quantitative), (±)-36 (35%), 37 (31%), 40 (78%);  
(ii) (±)-29,12 Et3N, [PdCl2(PPh3)2], CuI, DMF, 25 °C, 2.5–3 h, (±)-5 (72%), (±)-6 



























(±)-5  R = n-butyl
(±)-6  R = n-hexyl
(±)-7  R = sec-butyl
(±)-8  R = isopropyl
(±)-11  R = cyclohexyl
      30  R = n-butyl
      35  R = n-hexyl
(±)-36  R = sec-butyl
      37  R = isopropyl
      40  R = cyclohexyl
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Scheme 2ESI.  Synthesis of inhibitors (±)-9 and (±)-10.  (i) Mg, Et2O, reflux, 30 min;  
(ii) SO2Cl2, CH2Cl2, 0 °C → 25 °C;  (iii) propargyl amine, CH2Cl2, 0 °C → 25 °C, 
15–30 min, 38 (31%), 39 (30%);  (iv) (±)-29,12 Et3N, [PdCl2(PPh3)2], CuI, DMF, 

















(±)-9  R = cyclobutyl




38  R = cyclobutyl
39  R = cyclopentyl
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Scheme 3ESI.  Synthesis of inhibitors 12 and 13.  (i) Cs2CO3 or NaH, DMF, 50 °C, 
16 h or 8 h, 41 (37%), 42 (54%);  (ii) 26,12 Et3N, [PdCl2(PPh3)2], CuI, DMF, 25 °C, 
























  R = cyclopentyl
  R = cyclobutylmethyl
R
41  R = cyclopentyl
42  R = cyclobutylmethyl
12  R = cyclopentyl
13  R = cyclobutylmethyl  
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Scheme 4ESI.  Synthesis of inhibitor (±)-14.  (i) NaH, MeI, DMF, 25 °C, 1 h, 91%;  






















26  R = H
43  R = CH3
i
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Scheme 5ESI.  Synthesis of inhibitors (±)-15 – (±)-17.  (i) Et3N, [PdCl2(PPh3)2], CuI, 
















31  R = 4-morpholinyl
32  R = 1-piperidinyl
33  R = 1-pyrrolidinyl
i
(±)-15  R = 4-morpholinyl
(±)-16  R = 1-piperidinyl
(±)-17  R = 1-pyrrolidinyl  
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Scheme 6ESI.  Synthesis of inhibitors 19 – 21.  (i) NaH, DMF, 25 °C, 21 h or 15 h, 
44 (89%), 45 (67%);  (ii) 26 or 34,12 Et3N, [Pd(PPh3)4] or [PdCl2(PPh3)2], CuI, DMF, 
























  R = CH2CO2Et
  R =
R
CO2Me
 44  R = CH2CO2Et
 45  R = CO2Me
 20  R = CH2CO2Et, R' = cyclopropyl
 19  R = CH2CO2H.Et3N, R' = cyclopropyl
 21  R =                                   R' = CH2CF3CO2Me
iii
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Table 1ESI. X-ray co-crystal structure:  statistics for data collection and refinement. 
_____________________________________________________________________ 
Space Group    P213    
  
Unit cell length (Å)    137.3     
Resolution range (Å)    97.1–2.2   
  
Observed / unique reflections    271,731 / 43,998  
  
Wilson B (Å2)    48.6    
  
Completeness (%)    99.9 (100.0)    
Multiplicity/Rmerge (%)    6.2 (6.1) / 6.0 (69.0)   
<I/σ(I)>    19.4 (2.5)   
  
Rwork / Rfree (%)    22.7 (29.8) / 27.6 (38.0) 
  
r.m.s.d from ideal values, bond lengths (Å)  0.013 
r.m.s.d from ideal values, bond angles (°)  1.585    
B-factors 
Overall / main chain / side chain /   46.1 / 45.6 / 46.5 / 
water molecules / 22 / diphosphate / Cl– / Br– 43.5 / 56.1 / 50.4 / 46.5 / 32.4 
Residues in most favourable regions (%)  91.8    
  
Residues in additionally allowed regions (%) 7.5    
  
Cruickshanks DPIa (Å) based on Rfree   0.23    
  
_____________________________________________________________________      
 
Numbers in parenthesis represent the highest resolution bin of width approx. 0.12 Å. 
a Diffraction-component Precision Index.43 
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General Procedure B for the preparation of a sulfonamide from a sulfonyl 
chloride 
To a solution of propargyl amine (1.0 eq) in dry CH2Cl2, Et3N (1.1 eq) and the 
sulfonyl chloride (1.0 eq) were slowly added at 0 °C.  After completion of the 
addition, the mixture was left to stir at 25 °C for 15–30 min and concentrated in 
vacuo.  The residue was purified by CC (SiO2; EtOAc–cyclohexane 1:2). 
General procedure C for the base-mediated alkylation of 2324 
A solution of 2324 (1.0 eq) and NaH (1.1 eq) in dry DMF was left to stir at 25 °C for 
1 h.  The alkyl bromide (1.1 eq) in dry DMF was slowly added, and the mixture was 
left to stir at 25–50 °C for 8–21 h and concentrated in vacuo.  NaH was used as 
suspension of NaH in mineral oil (55–65%). 
General procedure D for the preparation of sulfonamides from bromides 
To a suspension of Mg turnings (1.7 eq) in dry Et2O, a solution of the alkyl bromide 
(1.0 eq) in dry Et2O was slowly added in small portions under strong stirring.  After 
the initial exothermic reaction had ceased, the mixture was further heated to reflux for 
30 min.  The suspension was cooled to 25 °C and slowly added to a solution of 
sulfuryl chloride (3.0 eq) in dry CH2Cl2 at 0 °C.  The mixture was warmed up to 
25 °C and concentrated in vacuo.  The residue was extracted with n-hexane and 
concentrated in vacuo.  The remaining oil was used without further purification and 
slowly added to a solution of propargyl amine (1.0 eq) and Et3N (1.1 eq) in dry 
CH2Cl2 at 0 °C.  After completion of the addition, the mixture was left to stir at 25 °C 
for 15–30 min and then concentrated in vacuo.  The residue was purified by CC 
(SiO2; EtOAc–cyclohexane 1:2) to afford the corresponding sulfonamide. 
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Preparation of the precursors 
N-Prop-2-yn-1-ylhexane-1-sulfonamide (35): 
General procedure B, starting from propargyl amine (0.13 cm3, 2.0 mmol), Et3N 
(0.30 cm3, 2.2 mmol) and hexanesulfonyl chloride (0.30 cm3, 2.0 mmol) in dry 
CH2Cl2 (15 cm3).  Purification by CC afforded 35 (387 mg, quantitative) as a yellow 
oil (Found C 52.9, H 8.4, N 6.9.  Calcd for C9H17NO2S: C 53.2, H 8.4, N 6.9%);  
νmax(neat)/cm-1 3274, 2930, 2860, 1431, 1325, 1251, 1143, 1078, 993, 920, 835, 663;  
δH(300 MHz, CDCl3) 0.90 (t, J = 6.9, 3 H), 1.28–1.48 (m, 6 H), 1.79–1.89 (m, 2 H), 
2.35 (t, J = 2.7, 1 H), 3.11–3.16 (m, 2 H), 3.96 (dd, J = 2.7, 6.3, 2 H), 4.44 (br s, 1 H);  
δC(75 MHz, CDCl3) 13.9, 22.3, 23.5, 27.9, 31.2, 32.6, 53.5, 72.9, 109.8;  EI-HR-MS: 
calcd for C9H16NO2S+ ([M-H]+): 202.0897; found: 202.0894.  
(±)-N-Prop-2-yn-1-ylbutane-2-sulfonamide ((±)-36): 
General procedure B, starting from propargyl amine (0.13 cm3, 2.0 mmol), Et3N 
(0.30 cm3, 2.2 mmol), and sec-butanesulfonyl chloride (0.13 cm3, 2.0 mmol) in dry 
CH2Cl2 (15 cm3).  Purification by CC afforded (±)-36 (120 mg, 35%) as a yellow oil;  
νmax(neat)/cm-1 3275, 2974, 2935, 2889, 1458, 1315, 1140, 1078, 985, 918, 853, 719, 
645;  δH(300 MHz, CDCl3) 1.02 (t, J = 7.5, 3 H), 1.38 (d, J = 6.9, 3 H), 1.49–1.64 (m, 
1 H), 2.00–2.13 (m, 1 H), 2.32 (t, J = 2.6, 1 H), 2.98-3.10 (m, 1 H), 3.93 (dd, J = 2.6, 
6.2, 2 H), 4.81 (br. s, 1 H);  δC(75 MHz, CDCl3) 11.2, 13.3, 23.4, 32.7, 59.7, 72.6, 
79.2;  EI-HR-MS: calcd for C7H13NNaO2S+ ([M+Na]+): 198.0565; found: 198.0560.  
N-Prop-2-yn-1-ylpropane-2-sulfonamide (37): 
General procedure B, starting from propargyl amine (0.13 cm3, 2.0 mmol), Et3N 
(0.30 cm3, 2.2 mmol) and isopropanesulfonyl chloride (0.23 cm3, 2.0 mmol) in dry 
CH2Cl2 (15 cm3).  Purification by CC afforded 37 (100 mg, 31%) as a red oil;  
νmax(neat)/cm-1 3274, 2956, 2930, 2863, 1458, 1324, 1248, 1143, 1076, 990, 925, 838, 
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668;  δH(300 MHz, CDCl3) 1.40 (d, J = 6.9, 6 H), 2.33 (t, J = 2.4, 1 H), 3.29 (sept, 
J = 6.9, 1 H), 3.94 (dd, J = 2.4, 6.0, 2 H), 4.75 (br s, 1 H);  δC(75 MHz, CDCl3) 16.5 
(2 C), 32.8, 53.9, 72.7, 79.2;  EI-HR-MS: calcd for C6H11NO2S+ ([M]+): 161.0510; 
found: 161.0497. 
N-Prop-2-yn-1-ylcyclobutanesulfonamide (38): 
General procedure D, starting from Mg turnings (100 mg, 4.2 mmol) in dry Et2O 
(4.0 cm3) and cyclobutyl bromide (0.20 cm3, 2.5 mmol) in dry Et2O (4.0 cm3); 
sulfuryl chloride  (0.60 cm3, 7.4 mmol) in dry CH2Cl2 (6.0 cm3); propargyl amine 
(0.13 cm3, 2.0 mmol) and Et3N (0.30 cm3, 2.2 mmol) in dry CH2Cl2 (15 cm3).  
Purification by CC afforded 38 (110 mg, 31%) as a brown oil;  νmax(neat)/cm-1 3274, 
2952, 2873, 1434, 1318, 1282, 1243, 1143, 1076, 1011, 913, 812, 737, 623;  
δH(300 MHz, CDCl3) 1.96–2.07 (m, 2 H), 2.29–2.41 (m, 2 H), 2.34 (t, J = 2.7, 1 H), 
2.45–2.58 (m, 2 H), 3.91–3.95 (m, 3 H), 4.57 (br s, 1 H);  δC(75 MHz, CDCl3) 16.8, 
23.9, 32.7, 55.0, 72.6, 79.3;  EI-HR-MS: calcd for C7H11NO2S+ ([M]+): 173.0505; 
found: 173.0507.  
N-Prop-2-yn-1-ylcyclopentanesulfonamide (39): 
General procedure D, starting from Mg turnings (150 mg, 6.3 mmol) in dry Et2O 
(4.0 cm3) and cyclopentyl bromide (0.36 cm3, 3.3 mmol) in dry Et2O (4.0 cm3); 
sulfuryl chloride  (0.90 cm3, 11.1 mmol) in dry CH2Cl2 (6.0 cm3); propargyl amine 
(0.18 cm3, 2.7 mmol) and Et3N (0.45 cm3, 3.3 mmol) in dry CH2Cl2 (15 cm3).  
Purification by CC afforded 39 (150 mg, 30%) as a brown oil that was taken directly 
to the next step without full characterisation;  νmax(neat)/cm-1 3279, 2963, 1640, 1493, 
1306, 1127, 1076, 972, 839, 783, 719;  δH(300 MHz, CDCl3) 1.57–1.70 (m, 2 H), 
1.76–1.89 (m, 2 H), 1.95–2.14 (m, 4 H), 2.34 (t, J = 2.7, 1 H), 3.61 (quint, J = 7.5, 
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1 H), 3.94–3.98 (m, 2 H), 4.54 (br s, 1 H);  EI-HR-MS: calcd for C8H12NO2S+ 
([M-H]+) 186.0584; found: 186.0585. 
N-Prop-2-yn-1-ylcyclohexanesulfonamide (40): 
General procedure B, starting from propargyl amine (0.13 cm3, 2.0 mmol), Et3N 
(0.30 cm3, 2.2 mmol) and cyclohexanesulfonyl chloride (0.30 cm3, 2.0 mmol) in dry 
CH2Cl2 (15 cm3).  Purification by CC afforded 40 (320 mg, 78%) as a yellow oil;  
νmax(neat)/cm-1 3273, 2938, 2860, 1454, 1317, 1269, 1144, 1078, 985, 893, 861, 838, 
668;  δH(300 MHz, CDCl3) 1.17–1.37 (m, 3 H), 1.48–1.61 (m, 2 H), 1.68–1.74 (m, 
1 H), 1.89–1.94 (m, 2 H), 2.20–2.25 (m, 2 H), 2.35 (t, J = 2.5, 1 H), 3.02 (tt, J = 3.5, 
12.0, 1 H), 3.95 (dd, J = 2.4, 6.0, 2 H), 4.41 (br s, 1 H);  δC(75 MHz, CDCl3) 25.1, 
25.2 (2 C), 26.3 (2 C), 32.7, 61.6, 72.6, 79.2;  EI-HR-MS: calcd for C9H14NO2S+ 
([M+H]+): 200.0740; found: 200.0742. 
4-Amino-1-cyclopentyl-5-iodopyrimidin-2(1H)-one (41): 
General procedure C, starting from 2324 (240 mg, 1 mmol), Cs2CO3 (360 mg, 
1.1 mmol) and cyclopentyl bromide (0.12 cm3, 1.1 mmol) in dry DMF (15 + 5.0 cm3).  
The mixture was left to stir at 50 °C for 16 h and concentrated in vacuo.  Purification 
by CC (SiO2; CH2Cl2–MeOH 96:4) afforded 41 (110 mg, 37%) as a white solid;  mp 
> 210 °C (decomposition);  νmax(neat)/cm-1 3441, 2953, 2867, 2661, 2567, 2235, 
2040, 2025, 1984, 1967, 1946, 1897, 1822, 1767, 1610, 1514, 1481, 1400, 1309, 
1283, 1243, 1189, 1099, 1067, 1026, 913, 850, 777, 725, 643;  δH(300 MHz, (CDCl3–
CD3OD 7:1) 1.43–1.72 (m, 6 H), 1.97–2.03 (m, 2 H), 4.79 (quint, J = 7.9, 1 H), 7.50 
(s, 1 H); δC(75 MHz, CDCl3–CD3OD 7:1) 23.7 (2 C), 31.6 (2 C), 56.1, 58.1, 147.5, 
155.9, 163.0;  MALDI-HR-MS: calcd for C9H13IN3O+ ([M+H]+): 306.0098; found: 
306.0103. 
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 4-Amino-1-(cyclobutylmethyl)-5-iodopyrimidin-2(1H)-one (42): 
General procedure C, starting from: 2324 (240 mg, 1 mmol), NaH (44 mg, 1.1 mmol) 
and cyclobutylmethyl bromide (0.12 cm3, 1.1 mmol) in dry DMF (15 + 5.0 cm3).  The 
mixture was left to stir at 50 °C for 8 h.  Purification by CC (SiO2; CH2Cl2–MeOH 
96:4) afforded 42 (164 mg, 54%) as a white solid (Found C 35.4, H 4.0, N 13.7.  
Calcd for C9H12IN3O: C 35.4, H 4.0, N 13.8%);  mp 154–156 °C;  νmax(neat)/cm-1 
2967, 2933, 2858, 2569, 2497, 2427, 1808, 1603, 1467, 1429, 1358, 1312, 1280, 
1241, 1191, 1156, 1128, 1015, 951, 906, 867, 773, 736, 676, 632;  δH(300 MHz, 
CD3OD) 1.75–2.06 (m, 6 H), 2.72 (quint, J = 7.6, 1 H), 3.79 (d, J = 7.6, 2 H), 8.02 (s, 
1 H);  δC(75 MHz, CD3OD) 19.0, 26.5 (2 C), 36.1, 55.6, 56.1, 153.4, 158.0, 165.8;  
MALDI-HR-MS: calcd for C9H13IN3O+ ([M+H]+): 306.0098; found: 306.0098. 
N-Methyl-N-prop-2-yn-1-ylcyclopropanesulfonamide (43): 
A supension of 2612 (87 mg, 0.55 mmol) and NaH (26 mg, 1.1 mmol) in dry DMF 
(7.0 cm3) was left to stir at 25 °C for 1 h.  Methyl iodide (68 mm3, 1.1 mmol) was 
added, and the mixture was left to stir at 25 °C for 1 h.  The resulting mixture was 
quenched with water (10 cm3) and extracted with CH2Cl2 (3 x 15 cm3).  The 
combined org. phases were dried over Na2SO4, filtered and concentrated in vacuo.  
Filtration through a plug of silica gel (EtOAc–cyclohexane 1:2) afforded 43 (87 mg, 
91%) as a yellow oil (Found C 48.35, H 6.4, N 7.9.  Calcd for C7H11NO2S: C 48.5, 
H 6.4, N 8.1%);  νmax(neat)/cm-1 3273, 2969, 1635, 1456, 1328, 1306, 1200, 1148, 
1067, 1041, 995, 927, 907, 888, 827, 783, 760, 742, 691;  δH(300 MHz, CDCl3) 0.96–
1.03 (m, 2 H), 1.16–1.21 (m, 2 H), 2.36 (t, J = 2.5, 1 H), 2.39–2.46 (m, 1 H), 2.96 (s, 
3 H), 4.06 (d, J = 2.5, 2 H);  δC(75 MHz, CDCl3) 5.1 (2 C), 27.3, 34.7, 39.8, 74.1, 
77.0;  HR-ESI-MS: calcd for C7H11NNaO2S+ ([M+Na]+): 196.0403; found: 196.0403. 
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Ethyl (4-Amino-5-iodo-2-oxopyrimidin-1(2H)-yl)acetate (44): 
General procedure C, starting from: 2324 (950 mg, 4.0 mmol), NaH (110 mg, 
4.4 mmol) and ethyl bromoacetate (740 mg, 4.4 mmol) in dry DMF (60 + 20 cm3). 
The mixture was left to stir at 25 °C for 21 h.  Purification by CC (SiO2; CH2Cl2–
MeOH 95:5) afforded 44 (1.2 g, 89%) as a white solid (Found C 29.8, H 3.1, N 13.1.  
Calcd for C8H10IN3O3: C 29.7, H 3.2, N 13.0%);  mp 207–209 °C;  νmax(neat)/cm-1 
3460, 2977, 2250, 1723, 1633, 1478, 1412, 1397, 1368, 1356, 1330, 1282, 1230, 
1207, 1093, 1012, 958, 920, 876, 819, 776, 731, 710, 645, 625;  δH(300 MHz, CDCl3–
CD3OD 7:1) 1.30 (t, J = 7.2, 3 H), 4.25 (q, J = 7.2, 2 H), 4.51 (s, 2 H), 7.57 (s, 1 H);  
δC(75 MHz, (CD3)2SO) 14.0, 49.6, 55.6, 60.9, 152.2, 154.5, 164.3, 168.4;  MALDI-
HR-MS: calcd for C8H11IN3O3+ ([M+H]+): 323.9840; found: 323.9846. 
Methyl 4-[(4-Amino-5-iodo-2-oxopyrimidin-1(2H)-yl)methyl]benzoate (45): 
General procedure C, starting from: 2324 (470 mg, 2.0 mmol), NaH (53 mg, 
2.2 mmol) and methyl 4-(bromomethyl)benzoate (500 mg, 2.2 mmol) in dry DMF 
(30 + 10 cm3).  The mixture was left to stir at 25 °C for 15 h.  Purification by 
CC (SiO2; CH2Cl2–MeOH 97:3) afforded 45 (520 mg, 67%) as a white solid (Found 
C 40.6, H 3.2, N 10.7.  Calcd for C13H13IN3O3: C 40.5, H 3.1, N 10.9%);  mp 228–
230 °C;  νmax(neat)/cm-1 3441, 3037, 2945, 1707, 1622, 1488, 1471, 1428, 1413, 
1367, 1347, 1320, 1275, 1216, 1189, 1104, 1017, 965, 943, 923, 872, 793, 772, 757, 
747, 706, 688, 645, 614; δH(300 MHz, CDCl3–CD3OD 7:1) 3.81 (s, 3 H), 4.91 (s, 
2 H), 7.26 (d, J = 8.3, 2 H), 7.57 (s, 1 H), 7.91 (d, J = 8.3, 2 H);  δC(75 MHz, CDCl3–
CD3OD 7:1) 51.8, 52.0, 56.4, 127.4 (2 C), 129.5, 129.8 (2 C), 140.9, 150.8, 156.1, 
164.0, 166.7; MALDI-HR-MS: calcd for C13H13IN3O3+ ([M+H]+): 385.9996; found: 
385.9992. 
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